Access Bio, Inc. Logo

Access Bio, Inc.

Develops and manufactures rapid diagnostic tests for infectious diseases for global health.

950130 | KO

Overview

Corporate Details

ISIN(s):
KR8840090003
LEI:
Country:
United States of America
Address:
65 Clyde Road Suite A, Somerset NJ
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Access Bio, Inc. is a biotechnology company dedicated to the prevention and early diagnosis of infectious diseases. It engages in the research, development, manufacturing, and marketing of in vitro rapid diagnostic tests (IVD), biosensors, and molecular diagnostic products. The company is a key partner in global health, recognized for its comprehensive portfolio of tests for diseases such as malaria, HIV, HPV, and COVID-19. Through its products, including the CareStart™ line, Access Bio focuses on providing high-quality, accessible diagnostic solutions to combat serious health threats worldwide, particularly in developing nations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean 3.2 KB
2025-08-18 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내 )
Korean 3.0 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.8 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.1 MB
2025-08-14 00:00
Earnings Release
반기또는분기매출액미달사실발생
Korean 6.0 KB
2025-08-14 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 관련)
Korean 3.2 KB
2025-08-14 00:00
Delisting Announcement
주권매매거래정지 (상장적격성 실질심사 대상 (사유발생))
Korean 4.6 KB
2025-05-20 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 26.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.9 MB
2025-04-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 88.3 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 28.5 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.6 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 26.7 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 2.8 MB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 15.7 KB

Automate Your Workflow. Get a real-time feed of all Access Bio, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Access Bio, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Access Bio, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Candel Therapeutics, Inc. Logo
Developing off-the-shelf viral immunotherapies to help the immune system fight solid tumors.
United States of America
CADL
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel
CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany
27N0
Canopy Growth Corp Logo
Produces diverse cannabis products for medical and recreational markets globally.
United States of America
CGC
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany
HIGH
CAPRICOR THERAPEUTICS, INC. Logo
Develops cell and exosome-based therapeutics for rare diseases like Duchenne muscular dystrophy.
United States of America
CAPR
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea
214370
Caribou Biosciences, Inc. Logo
Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.
United States of America
CRBU
Carisma Therapeutics Inc. Logo
Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.
United States of America
CARM
Cartesian Therapeutics, Inc. Logo
Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.
United States of America
RNAC

Talk to a Data Expert

Have a question? We'll get back to you promptly.